<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072344</url>
  </required_header>
  <id_info>
    <org_study_id>AT005074</org_study_id>
    <nct_id>NCT01072344</nct_id>
  </id_info>
  <brief_title>Long Term Chamomile Therapy for Anxiety</brief_title>
  <official_title>Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prior research has shown that chamomile may be an effective, short-term anti-anxiety
      treatment. This study will examine the initial and long-term benefits of chamomile extract
      therapy for the prevention of recurrent anxiety disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anxiety disorders are among the most common psychiatric conditions. They affect up to 25% of
      the US adult population. Generalized anxiety disorder (GAD) is a chronic, recurrent form of
      the disorder. Although benzodiazepines and serotonin reuptake inhibitors have become the
      mainstay therapy of GAD, these drugs are often associated with unwanted side effects,
      habituation, and withdrawal symptoms. Many individuals decline using conventional drug
      therapy for financial, cultural, or personal reasons such as the stigma of mental illness. As
      a result, many individuals will seek alternative therapy for their anxiety symptoms. The
      identification of effective alternative therapies for GAD would be of particular relevance.
      Among alternative therapies for anxiety, chamomile has been used as a traditional herbal
      medicine for its calming effect. It is well tolerated and demonstrates pharmacological
      activity in animal models of anxiety. Despite its widespread use and availability, there has
      been only one clinical trial of chamomile safety and efficacy in GAD. The current application
      seeks to build upon the results of that prior chamomile study. In that 8-week, double-blind,
      placebo-controlled trial, we found a significant superiority of chamomile (vs. placebo) in
      reducing GAD symptoms. We also found chamomile to be exceedingly well tolerated (vs.
      placebo). The current application seeks to extend these promising preliminary results by
      conducting a randomized, double-blind, parallel group, placebo-substitution, long-term safety
      and efficacy study of chamomile in preventing GAD relapse. For specific aim #1 we will ask:
      &quot;Does long-term chamomile therapy (vs. placebo) prolong the time to relapse of anxiety
      symptoms following recovery from GAD?&quot; To answer this question, 180 patients with moderate to
      severe GAD will receive open-label chamomile extract 500-1,500 mg daily for 8 weeks.
      Responders to chamomile, who remain well for 4 additional weeks of consolidation therapy,
      will be randomized to double-blind continuation therapy with chamomile 500-1,500 mg daily or
      placebo for an additional 26 weeks. We hypothesize that continuation chamomile therapy will
      result in a prolonged time to relapse (vs. placebo). For specific aim #2 we will ask: &quot;What
      is the relative safety and tolerability of long-term chamomile therapy (vs. placebo) in
      patients who have recovered from GAD?&quot; To answer this question, we will examine the following
      outcome measures: (i) the proportion of patients in each treatment condition who relapse;
      (ii) the frequency, severity, and duration of treatment-emergent adverse events; (iii) the
      frequency of discontinuation symptoms during initial double-blind therapy; and, (iv) the
      frequency of early study discontinuation. We hypothesize that chamomile therapy will result
      in a lower proportion of anxiety relapses and a lower study discontinuation rate (vs.
      placebo). We further hypothesize that chamomile therapy will result in a similar frequency of
      discontinuation symptoms and treatment-emergent adverse events (vs. placebo).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Relapse in Each Treatment Condition.</measure>
    <time_frame>26 weeks</time_frame>
    <description>The primary outcome was time to relapse during continuation therapy, analyzed using Cox proportional hazards. Relapse is dichotomously defined as an increase in CGI/S (a clinician-rated global measure of anxiety's severity) score from ≤ 3 (at study visit 6) to ≥ 4 (on two consecutive scheduled or unscheduled study visits ≥ 2 weeks apart) plus meeting DSM IV-TR criteria for GAD (minus the 6-month time criterion).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Subjects in Each Treatment Condition Who Relapse.</measure>
    <time_frame>26 weeks</time_frame>
    <description>The proportion of subjects in each treatment condition who relapsed after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, Severity, and Duration of Treatment-emergent Adverse Events.</measure>
    <time_frame>26 weeks</time_frame>
    <description>We will report the frequency, severity, and duration of treatment-emergent adverse events by treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Discontinuation Symptoms at the Start of Double-blind Therapy in Each Treatment Condition.</measure>
    <time_frame>26 weeks</time_frame>
    <description>Discontinuation emergent signs and symptoms checklist (DESS) is a patient-rated measure of the presence and severity of discontinuation symptoms occurring after medication discontinuation. %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Early Study Discontinuation in Each Treatment Condition.</measure>
    <time_frame>26 weeks</time_frame>
    <description>This is the # of subjects who discontinued the study during randomization phase due to other reasons.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Chamomile Extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmaceutical grade oral chamomile extract.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pharmaceutical grade lactose monohydrate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chamomile (Matricaria recutita)</intervention_name>
    <description>500 mg 3 times daily</description>
    <arm_group_label>Chamomile Extract</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Chamomile</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women at least 18 years old (all races and ethnicity)

          -  DSM IV diagnosis of GAD as the primary anxiety disorder

          -  Baseline GAD-7 score ≥ 10

          -  Baseline CGI/S score at least 4

          -  Not taking anti-anxiety medication (e.g., Benzodiazepines, buspirone, antidepressants)

          -  Not taking antidepressant, mood stabilizer, or tranquilizer therapy for a prior DSM IV
             Axis I mood disorder that is in remission

          -  Able to understand and provide informed consent

          -  Able to participate in a 38-week study

        Exclusion Criteria:

          -  Patients &lt; 18 years old

          -  Primary DSM IV Axis I anxiety disorder other than GAD (e.g., panic disorder with or
             without agoraphobia, phobia disorder, acute stress disorder, social anxiety disorder,
             obsessive-compulsive disorder, post-traumatic stress disorder, substance-induced
             anxiety disorder)

          -  Current DSM IV Axis I psychotic disorder

          -  Substance abuse or dependence within the prior 3 months

          -  Current DSM IV Axis I bipolar or major depressive disorder [Note: Patients with
             co-morbid depressive disorder NOS (e.g., minor depression, recurrent brief depressive
             disorder, or premenstrual dysphoric disorder (PMDD)] will not be excluded

          -  Unstable medical condition

          -  Allergy to chamomile

          -  Documented allergy to plants of the asteraceae family (e.g., ragweed, asters,
             chrysanthemum)

          -  Allergic to mugwort or birch pollen

          -  Concurrent anti-anxiety tranquilizer, antidepressant or mood stabilizer therapy

          -  Concurrent use of over-the-counter anti-anxiety and/or antidepressant preparations
             (e.g., chamomile, St. John's Wort, kava kava)

          -  Concurrent use of established antidepressant, mood stabilizer, or tranquilizer therapy
             for pre-existing affective disorder. [Note: Patients with a history of affective
             disorder (in remission) who are not currently taking antidepressant, mood stabilizer,
             or tranquilizer therapy are not excluded from the trial]

          -  Women of child-bearing potential not willing to use a medically proven form of
             contraception

          -  Positive pregnancy test

          -  Actively suicidal or suicide attempt within the preceding 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun J Mao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Depression Research Unit</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-3309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2010</study_first_posted>
  <results_first_submitted>April 28, 2017</results_first_submitted>
  <results_first_submitted_qc>June 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 6, 2017</results_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <keyword>Chamomile</keyword>
  <keyword>Herbal Remedy</keyword>
  <keyword>Complementary and Alternative Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study has 3 phases. The 1st phase is open label cham.(N=179), subjects meeting response criteria enter 2nd phase (N=93), the consolidation phase of open label chamomile. At the end of 2nd phase, if subjects still meet response criteria, they will enter the 3rd phase (N=93). In the 3rd phase, subjects will be randomized to chamomile vs. placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Chamomile Extract</title>
          <description>Pharmaceutical grade oral chamomile extract.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Pharmaceutical grade lactose monohydrate.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Relasped-reached end point</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chamomile Extract</title>
          <description>Pharmaceutical grade oral chamomile extract.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Pharmaceutical grade lactose monohydrate.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.2" spread="14.3"/>
                    <measurement group_id="B2" value="45.4" spread="16.1"/>
                    <measurement group_id="B3" value="47.3" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Relapse in Each Treatment Condition.</title>
        <description>The primary outcome was time to relapse during continuation therapy, analyzed using Cox proportional hazards. Relapse is dichotomously defined as an increase in CGI/S (a clinician-rated global measure of anxiety's severity) score from ≤ 3 (at study visit 6) to ≥ 4 (on two consecutive scheduled or unscheduled study visits ≥ 2 weeks apart) plus meeting DSM IV-TR criteria for GAD (minus the 6-month time criterion).</description>
        <time_frame>26 weeks</time_frame>
        <population>All 93 subjects started randomization phase of the study were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Chamomile Extract</title>
            <description>Pharmaceutical grade oral chamomile extract.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pharmaceutical grade lactose monohydrate.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relapse in Each Treatment Condition.</title>
          <description>The primary outcome was time to relapse during continuation therapy, analyzed using Cox proportional hazards. Relapse is dichotomously defined as an increase in CGI/S (a clinician-rated global measure of anxiety's severity) score from ≤ 3 (at study visit 6) to ≥ 4 (on two consecutive scheduled or unscheduled study visits ≥ 2 weeks apart) plus meeting DSM IV-TR criteria for GAD (minus the 6-month time criterion).</description>
          <population>All 93 subjects started randomization phase of the study were included in the analysis</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="8.4"/>
                    <measurement group_id="O2" value="6.3" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Subjects in Each Treatment Condition Who Relapse.</title>
        <description>The proportion of subjects in each treatment condition who relapsed after randomization</description>
        <time_frame>26 weeks</time_frame>
        <population>During phase II consolidation phase, treatment responders were randomized to either 26 weeks of continuation chamomile therapy or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Chamomile Extract</title>
            <description>Pharmaceutical grade oral chamomile extract.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pharmaceutical grade lactose monohydrate.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Subjects in Each Treatment Condition Who Relapse.</title>
          <description>The proportion of subjects in each treatment condition who relapsed after randomization</description>
          <population>During phase II consolidation phase, treatment responders were randomized to either 26 weeks of continuation chamomile therapy or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency, Severity, and Duration of Treatment-emergent Adverse Events.</title>
        <description>We will report the frequency, severity, and duration of treatment-emergent adverse events by treatment arm.</description>
        <time_frame>26 weeks</time_frame>
        <population>During phase II consolidation phase, treatment responders were randomized to either 26 weeks of continuation chamomile therapy or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Chamomile Extract</title>
            <description>Pharmaceutical grade oral chamomile extract.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pharmaceutical grade lactose monohydrate.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency, Severity, and Duration of Treatment-emergent Adverse Events.</title>
          <description>We will report the frequency, severity, and duration of treatment-emergent adverse events by treatment arm.</description>
          <population>During phase II consolidation phase, treatment responders were randomized to either 26 weeks of continuation chamomile therapy or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Discontinuation Symptoms at the Start of Double-blind Therapy in Each Treatment Condition.</title>
        <description>Discontinuation emergent signs and symptoms checklist (DESS) is a patient-rated measure of the presence and severity of discontinuation symptoms occurring after medication discontinuation. %</description>
        <time_frame>26 weeks</time_frame>
        <population>These are responders at the end of Phase II of the study and then were randomized in Phase III of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Chamomile Extract</title>
            <description>Pharmaceutical grade oral chamomile extract.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pharmaceutical grade lactose monohydrate.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Discontinuation Symptoms at the Start of Double-blind Therapy in Each Treatment Condition.</title>
          <description>Discontinuation emergent signs and symptoms checklist (DESS) is a patient-rated measure of the presence and severity of discontinuation symptoms occurring after medication discontinuation. %</description>
          <population>These are responders at the end of Phase II of the study and then were randomized in Phase III of the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># of subject had no new symptoms after randomizat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of subject had &gt;=1 new symptom after randomizati</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Early Study Discontinuation in Each Treatment Condition.</title>
        <description>This is the # of subjects who discontinued the study during randomization phase due to other reasons.</description>
        <time_frame>26 weeks</time_frame>
        <population>These are responders at the end of Phase II of the study and were then randomized into Phase III of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Chamomile Extract</title>
            <description>Pharmaceutical grade oral chamomile extract.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pharmaceutical grade lactose monohydrate.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Early Study Discontinuation in Each Treatment Condition.</title>
          <description>This is the # of subjects who discontinued the study during randomization phase due to other reasons.</description>
          <population>These are responders at the end of Phase II of the study and were then randomized into Phase III of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># Lost to Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># withdrawn due to non-compliance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Chamomile Extract</title>
          <description>Pharmaceutical grade oral chamomile extract.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Pharmaceutical grade lactose monohydrate.
Chamomile (Matricaria recutita): 500 mg 3 times daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased platelet count</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ringing in ears</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Herbal taste</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sleep paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>taste perversion</sub_title>
                <description>taste perversion caused by strong chamomile smell</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jun Mao</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-0866</phone>
      <email>maoj@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

